AbbVie Inc (ABBV)

pos +1.02
Today's Range: 58.75 - 60.02 | ABBV Avg Daily Volume: 11,664,600
Last Update: 09/17/14 - 4:00 PM EDT
Volume: 14,251,947
YTD Performance: 10.96%
Open: $58.89
Previous Close: $58.60
52 Week Range: $44.02 - $58.77
Oustanding Shares: 1,591,699,124
Market Cap: 92,207,130,253
6-Month Chart
TheStreet Ratings Grade for ABBV
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 5 5 4 4
Moderate Buy 0 0 0 1
Hold 2 2 3 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.57 1.57 1.86 2.05
Latest Dividend: 0.42
Latest Dividend Yield: 2.90%
Dividend Ex-Date: 07/11/14
Price Earnings Ratio: 22.45
Price Earnings Comparisons:
ABBV Sector Avg. S&P 500
22.45 12.60 28.58
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
8.52% 27.89% 0.00%
Revenue 5.40 0.00 0.00
Net Income 53.70 0.00 0.00
EPS 0.00 0.00 0.00
Earnings for ABBV:
Revenue 18.38B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $0.77 $0.88 $3.14 $4.02
Number of Analysts 3 2 6 6
High Estimate $0.78 $0.92 $3.18 $4.30
Low Estimate $0.77 $0.83 $3.10 $3.76
Prior Year $0.82 $0.82 $3.14 $3.14
Growth Rate (Year over Year) -5.69% 6.71% 0.05% 27.80%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
Jul 28, 2014 | 8:03 AM EDT
ABBV was upgraded to Buy from Neutral, UBS said. Reflective of accretive Shire deal. $67 price target. 
Jul 23, 2014 | 7:41 AM EDT
ABBV was placed on the US 1 list, according to Bank of America/Merrill Lynch said. Estimates also increased, given higher expected Hepa...

This Morning's Market Setup Real Money Pro($)

Where it began.
May 07, 2014 | 8:12 AM EDT
ABBV was upgraded from Equal-weight to Overweight, Morgan Stanley said. $60 price target. Company has an attractive pipeline and can ge...
The market wants companies that are taking share with minimal spending.
Investors may be worried about Sovaldi's price.
Its potent hepatitis C treatment is not a boon for shareholders.

Dividend D-Day Coming Real Money Pro($)

The goal is always simply to get out where we got in.
Mar 19, 2014 | 7:33 AM EDT
ABBV cut its number, Jefferies said. Competitive data in Hep C, pay for delay litigation re Androgel. $60 price target. 
Dec 19, 2013 | 7:48 AM EST
ABBV was downgraded from Overweight to Equal-weight, Morgan Stanley said. Valuation call, based on a $57 price target. 

Columnist Conversations

Market gives up most of its afternoon gains after investors have time to digest comments from Federal Reserve ...
Quick service restaurant Panera Bread (PNRA) carved out a new 52-week low of $142.41 back on July 25th. It has...
My first entry in EOG ended up failing....but here's something to be aware of....IF it can clear the 106.80 ar...
With much of the talk in Monday's drubbing about selling high beta in front of Alibaba, it seems that issue wa...


Columnist Tweets


Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.